These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6776566)

  • 21. The identification of LSD-like hallucinogens using the chronic spinal dog.
    Martin WR; Vaupel DB; Nozaki M; Bright LD
    Drug Alcohol Depend; 1978 Mar; 3(2):113-23. PubMed ID: 272982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats.
    Commissaris R; Lyness WH; Cordon JJ; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Nov; 13(5):621-6. PubMed ID: 7443731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the specificity of a cat behavior model for the study of hallucinogens.
    Marini JL; Sheard MH
    Eur J Pharmacol; 1981 Apr; 70(4):479-87. PubMed ID: 7238573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of hallucinogens on blind monkeys.
    Siegel RK; Brewster JM; Johnson CA; Jarvik ME
    Int Pharmacopsychiatry; 1976; 11(3):150-6. PubMed ID: 11193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and behavioral components of tolerance to LSD and mescaline in rats.
    Murray TF; Craigmill AL; Fischer GJ
    Pharmacol Biochem Behav; 1977 Sep; 7(3):239-44. PubMed ID: 928480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EEG and behavioral effects of 2-5-methoxy-4-methyl-amphetamine (DOM, STP).
    Florio V; Lipparini F; Scotti de Carolis A; Longo VG
    Arch Int Pharmacodyn Ther; 1969 Jul; 180(1):81-8. PubMed ID: 5357012
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination.
    Baker LE; Taylor MM
    Pharmacol Biochem Behav; 1997 Aug; 57(4):737-48. PubMed ID: 9259001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push-pull cannula.
    Tilson HA; Sparber SB
    J Pharmacol Exp Ther; 1972 Jun; 181(3):387-98. PubMed ID: 5033008
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycogen phosphorylase levels in the brain of rats treated with psychotomimetic drugs and with tranquilizers.
    Iriye TT; Kuna A; Simmonds FA
    Biochem Pharmacol; 1965 Jul; 14(7):1169-71. PubMed ID: 5892600
    [No Abstract]   [Full Text] [Related]  

  • 30. Tolerance and cross-tolerance among psychotomimetic drugs.
    Appel JB; Freedman DX
    Psychopharmacologia; 1968 Sep; 13(3):267-74. PubMed ID: 5679628
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of hallucinogens and psycholeptic drugs on blood pressure reflexes and behavioral reactions in nonanesthetized cats.
    Balint GA
    Isr J Med Sci; 1972 Apr; 8(4):556-8. PubMed ID: 5034804
    [No Abstract]   [Full Text] [Related]  

  • 32. Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens.
    Marini JL; Jacobs BL; Sheard MH; Trulson ME
    Psychopharmacology (Berl); 1981; 73(4):328-31. PubMed ID: 6789353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral effects of intracerebroventricular administration of LSD, DOM, mescaline or lisuride.
    Mokler DJ; Rech RH
    Pharmacol Biochem Behav; 1984 Aug; 21(2):281-7. PubMed ID: 6483939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychoactive compounds and audiogenic seizure susceptibility.
    Boggan WO
    Life Sci; 1973 Jul; 13(2):151-9. PubMed ID: 4751412
    [No Abstract]   [Full Text] [Related]  

  • 35. 2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug.
    Snyder SH; Faillace L; Hollister L
    Science; 1967 Nov; 158(3801):669-70. PubMed ID: 4860952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A behavioral comparison of Nexus, cathinone, BDB, and MDA.
    Bronson ME; Jiang W; DeRuiter J; Clark CR
    Pharmacol Biochem Behav; 1995; 51(2-3):473-5. PubMed ID: 7667371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LSD mescaline and serotonin injected into medial raphe nucleus potentiate apomorphine hypermotility.
    Fink H; Oelssner W
    Eur J Pharmacol; 1981 Nov; 75(4):289-96. PubMed ID: 7318915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroencephalographic studies on the development of tolerance and cross tolerance to mescaline in the rat.
    Colasanti B; Khazan N
    Psychopharmacologia; 1975 Sep; 43(3):201-5. PubMed ID: 171694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological and toxicological effects of beta-3,4-methylenedioxyamphetamine isomers.
    Marquardt GM; DiStefano V; Ling LL
    Toxicol Appl Pharmacol; 1978 Sep; 45(3):675-83. PubMed ID: 725923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.